Trial Condition(s):

Papulopustular Rosacea

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Bayer Identifier:

15386

ClinicalTrials.gov Identifier:

NCT01257919

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel.

Assessment of safety after repeated skin application.

Inclusion Criteria
- diagnosis of moderate papulopustular rosacea
- free of any clinically significant disease
Exclusion Criteria
- body weight less than 50 or more than 130 kg
- clinically significant disease which could interfere with the study

Trial Summary

Enrollment Goal
21
Trial Dates
black-arrow
Phase
1
Could I receive a placebo?
No
Products
Finacea® (azelaic acid) Foam, 15% (Azelaic Acid, BAY39-6251)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Novum Pharmaceutical Research Services of Nevada Inc.

Las Vegas, United States, 89121

Status
Completed
 

Trial Design